HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers.
On May 23, 2019, our board of directors appointed Laura Godlewski as our principal accounting officer, effective immediately, replacing Shaun D. McMeans, our Senior Vice President and Chief Financial Officer, in that capacity. Mr. McMeans continues to serve as our Senior Vice President and Chief Financial Officer, as well as our principal financial officer.
Ms. Godlewski, age 40, has served as our Vice President of Accounting and Financial Reporting since July 2017, and continues to serve in this capacity following her appointment as our principal accounting officer. From January 2015 to July 2017, Ms. Godlewski served as our Corporate Controller. Before joining us, Ms. Godlewski served as Chief Financial Officer of VisionQuest National, Inc., a human services organization, from June 2014 to January 2015. From June 2008 to May 2014, Ms. Godlewski served in various roles of increasing responsibility at The Providence Service Corporation, a publicly traded behavioral health company, including Human Services Division Director of Finance, Corporate Director of Finance and Accounting and Interim Controller. Ms. Godlewski began her career at KPMG LLP in 2001, where she served in audit and transaction services roles, including Audit Manager from 2006 to 2008. Ms. Godlewski received her B.A. in Accounting from Michigan State University and is a certified public accountant.
About HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM)
HTG Molecular Diagnostics, Inc. is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development. The Company’s HTG Edge and HTG EdgeSeq platforms automate the molecular profiling of genes and gene activity using its nuclease protection chemistry on a range of biological samples. The Company’s HTG EdgeSeq chemistry, together with its HTG Edge or HTG EdgeSeq instrumentation and software, automates and adapts its nuclease protection chemistry to enable analysis using next generation sequencing (NGS) instrumentation. The HTG EdgeSeq system utilizes substantially the same sample preparation reagents as its original chemistry, but allows for read out on an NGS instrument.
